{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:21:20Z","timestamp":1794385280076,"version":"4.9.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Nigeria\u2019s Federal Capital Territory\u00a0(FCT) launched annual mass drug administration (MDA) in its four lymphatic filariasis (LF)-endemic councils in 2011, achieving sustained high coverage and pre-transmission assessment survey success. This study aimed to confirm transmission interruption in Bwari and Gwagwalada and to evaluate post-MDA surveillance efficacy in Abaji and Kuje.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Transmission Assessment Surveys (TAS) were systematically conducted in four distinct evaluation units (EUs) within the FCT. TAS\u00a01 was carried out in Bwari and Gwagwalada EUs that had recently achieved pre-TAS thresholds indicating potential interruption of transmission, whereas TAS\u00a02 was conducted in Abaji and Kuje EUs, where MDA had been discontinued since 2021 following successful TAS\u00a01 evaluations. Abbott Filarial Test Strips (FTS) were employed to test children aged 6\u20137\u00a0years attending selected schools. Data collection adhered to standardized WHO guidelines, utilizing both paper-based and electronic data-capture tools to enhance accuracy and reduce human error.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 6,448 children participated in surveys across the four EUs, with gender distribution closely balanced (53% male, 47% female). In TAS\u00a01 (Bwari and Gwagwalada), no LF-positive cases were identified well below the WHO-defined critical cutoff of 18 cases. In TAS\u00a02 (Abaji and Kuje), a single LF-positive case was detected in Abaji, still below the critical threshold. Participant refusal rates were minimal, reflecting strong community support and engagement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The findings provide compelling evidence of significant progress toward LF elimination in Nigeria\u2019s FCT; however, the single positive case in Abaji underscores the continued importance of vigilant surveillance and integrated vector-management strategies to maintain elimination status and guard against residual transmission.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40249-025-01333-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:40:34Z","timestamp":1752136834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the effectiveness of mass drug administration on lymphatic filariasis transmission and assessment of post-mass drug administration surveillance in Nigeria\u2019s Federal Capital Territory"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2565-4735","authenticated-orcid":false,"given":"Juliana Ajuma","family":"Amanyi-Enegela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kumbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizah","family":"Okunade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Ashikeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinpan","family":"Ishaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girija","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Enan","family":"Adamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Aderogba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Makau-Barasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achai","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosede Eunice","family":"Ogundipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinwe","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"issue":"12","key":"1333_CR1","first-page":"145","volume":"98","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global programme to eliminate lymphatic filariasis: progress report 2022. Wkly Epidemiol Rec. 2023;98(12):145\u201360.","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"1333_CR2","first-page":"181","volume":"12","author":"JC Anosike","year":"2005","unstructured":"Anosike JC, Nwoke BE, Ajayi EG, Onwuliri CO, Okoro OU, Oku EE, et al. Lymphatic filariasis among the Ezza people of Ebonyi State, eastern Nigeria. Ann Agric Environ Med. 2005;12(2):181\u20136.","journal-title":"Ann Agric Environ Med"},{"issue":"40","key":"1333_CR3","first-page":"565","volume":"99","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global programme to eliminate lymphatic filariasis: progress report 2023. Wkly Epidemiol Rec. 2024;99(40):565\u201376.","journal-title":"Wkly Epidemiol Rec"},{"key":"1333_CR4","volume-title":"Lymphatic filariasis: key facts","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Lymphatic filariasis: key facts. Geneva: WHO; 2019."},{"issue":"Suppl 1","key":"1333_CR5","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1093\/inthealth\/ihaa058","volume":"13","author":"K Deribe","year":"2020","unstructured":"Deribe K, Bakajika DK, Zoure HM, Gyapong JO, Molyneux DH, Rebollo MP. African regional progress and status of the programme to eliminate lymphatic filariasis: 2000\u20132020. Int Health. 2020;13(Suppl 1):S22\u20137.","journal-title":"Int Health"},{"key":"1333_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1756-3305-6-39","volume":"6","author":"PN Okorie","year":"2013","unstructured":"Okorie PN, Ademowo OG, Saka Y, Davies E, Okoronkwo C, Bockarie MJ, et al. Micro-stratification overlap mapping of lymphatic filariasis in Nigeria. Parasit Vectors. 2013;6:39.","journal-title":"Parasit Vectors"},{"key":"1333_CR7","unstructured":"World Health Organization. Resolution WHA50.29: elimination of lymphatic filariasis as a public health problem. Geneva: WHO; 1997."},{"key":"1333_CR8","unstructured":"World Health Organization. Monitoring and epidemiological assessment of mass drug administration in the Global Programme to Eliminate Lymphatic Filariasis. WHO Tech Rep Ser. 2001."},{"key":"1333_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-3305-7-46","volume":"7","author":"MA Brady","year":"2014","unstructured":"Brady MA. The global alliance to eliminate lymphatic filariasis: reaching the vision by scaling up, scaling down, and reaching out. Parasit Vectors. 2014;7:46.","journal-title":"Parasit Vectors"},{"key":"1333_CR10","unstructured":"World Health Organization. Guidelines for stopping mass drug administration and verifying elimination of lymphatic filariasis. WHO\/HTM\/NTD\/PCT\/2011.4. Geneva; 2011."},{"key":"1333_CR11","unstructured":"World Health Organization. Transmission assessment surveys in the Global Programme to Eliminate Lymphatic Filariasis. WHO\/HTM\/NTD\/PCT\/2013.7. Geneva; 2013."},{"issue":"6","key":"1333_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3347\/kjp.2020.58.6.627","volume":"58","author":"Y Santoso","year":"2020","unstructured":"Santoso Y, Yahya SY, Suryaningtyas NH, Taviv Y, Yenni A, et al. Risk of recrudescence of lymphatic filariasis after post-MDA surveillance in Belitung District, Indonesia. Korean J Parasitol. 2020;58(6):627\u201334.","journal-title":"Korean J Parasitol"},{"key":"1333_CR13","unstructured":"Federal Ministry of Health, Nigeria. Nigeria National Neglected Tropical Diseases Master Plan, 2023 \u2013 2027. Abuja: Author. Retrieved from the ESPEN portal; 2024."},{"key":"1333_CR14","doi-asserted-by":"publisher","first-page":"1033802","DOI":"10.3389\/fitd.2022.1033802","volume":"3","author":"J Amanyi-Enegela","year":"2022","unstructured":"Amanyi-Enegela J, Kumbur J, Burn N, Sankar G, Davies E, Ishaya R, et al. Assessment of the progress toward elimination of lymphatic filariasis in the Federal Capital Territory-Abuja, Nigeria. Front Trop Dis. 2022;3:1033802.","journal-title":"Front Trop Dis"},{"key":"1333_CR15","unstructured":"Federal Capital Territory Administration [FCTA]. FCT at a glance: Facts and figures 2020. Abuja, Nigeria: Department of Policy, Research & Statistics; 2021."},{"key":"1333_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1756-3305-4-90","volume":"4","author":"SM Njenga","year":"2011","unstructured":"Njenga SM, Mwandawiro CS, Wamae CN, Mukoko DA, Omar AA, Shimada M, et al. Sustained reduction in lymphatic filariasis prevalence despite missed MDA rounds under mosquito-net coverage. Parasit Vectors. 2011;4:90.","journal-title":"Parasit Vectors"},{"key":"1333_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13071-019-3525-5","volume":"12","author":"PM Boko-Collins","year":"2019","unstructured":"Boko-Collins PM, Ogouyemi-Hounto A, Adjinacou-Badou EA, Gbaguidi-Saizonou L, Dossa NI, Dare A, et al. Impact of treatment on lymphatic filariasis in 13 districts of Benin. Parasit Vectors. 2019;12:276.","journal-title":"Parasit Vectors"},{"issue":"4","key":"1333_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002080","volume":"7","author":"YK Sodahlon","year":"2013","unstructured":"Sodahlon YK, Dorkenoo AM, Morgah K, Nabiliou K, Agbo K, et al. Togo\u2019s progress toward LF elimination through MDA and morbidity alleviation. PLoS Negl Trop Dis. 2013;7(4): e2080.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9515","key":"1333_CR19","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S0140-6736(06)68426-2","volume":"367","author":"RM Ramzy","year":"2006","unstructured":"Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis\u00a0in Egypt: a comprehensive assessment. Lancet. 2006;367(9515):992\u20139.","journal-title":"Lancet"},{"key":"1333_CR20","unstructured":"World Health Organization. Guideline: Alternative mass drug administration regimens to eliminate lymphatic filariasis. WHO\/HTM\/NTD\/PCT\/2017.07. Geneva; 2017."},{"key":"1333_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12889-017-4414-5","volume":"17","author":"A Silumbwe","year":"2017","unstructured":"Silumbwe A, Zulu JM, Halwindi H, Jacobs C, Zgambo J, Dambe R, et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health. 2017;17:484.","journal-title":"BMC Public Health"},{"issue":"10","key":"1333_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000317","volume":"2","author":"EA Ottesen","year":"2008","unstructured":"Ottesen EA, Hooper PJ, Bradley M, Biswas G. Health impact of eight years of the global programme to eliminate lymphatic filariasis. PLoS Negl Trop Dis. 2008;2(10): e317.","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"1333_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003328","volume":"8","author":"K Ichimori","year":"2014","unstructured":"Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, et al. Global programme to eliminate lymphatic filariasis: the processes underlying programme success. PLoS Negl Trop Dis. 2014;8(12): e3328.","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"1333_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003281","volume":"8","author":"RU Rao","year":"2014","unstructured":"Rao RU, Nagodavithana KC, Samarasekera SD, Wijegunawardana AD, Premakumara WDY, et al. Comprehensive assessment of lymphatic filariasis in Sri Lanka six years after MDA. PLoS Negl Trop Dis. 2014;8(11): e3281.","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"1333_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008644","volume":"14","author":"BS Collyer","year":"2020","unstructured":"Collyer BS, Irvine MA, Hollingsworth TD, Bradley M, Anderson RM. Defining a prevalence level to describe elimination of lymphatic filariasis transmission and designing monitoring and evaluation programmes after cessation of MDA. PLoS Negl Trop Dis. 2020;14(10): e0008644.","journal-title":"PLoS Negl Trop Dis"},{"key":"1333_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2023-000534","volume":"2","author":"BM Martin","year":"2024","unstructured":"Martin BM, Restrepo AC, Mayfield HJ, Lau CL. Towards global elimination of lymphatic filariasis: application of spatial epidemiological methods. BMJ Public Health. 2024;2: e000534.","journal-title":"BMJ Public Health"},{"issue":"9","key":"1333_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005914","volume":"11","author":"CL Lau","year":"2017","unstructured":"Lau CL, Sheridan S, Ryan S, Roineau M, Andreosso A, Fuimaono S, et al. Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa eight years after stopping mass drug administration. PLoS Negl Trop Dis. 2017;11(9): e0005914.","journal-title":"PLoS Negl Trop Dis"},{"key":"1333_CR28","doi-asserted-by":"publisher","first-page":"107790","DOI":"10.1016\/j.ijid.2025.107790","volume":"1","author":"CA Boateng","year":"2025","unstructured":"Boateng CA, Afatodzie MS, McLure A, Kwansa-Bentum B, de Souza DK. Lymphatic filariasis transmission 10 years after stopping mass drug administration in the Gomoa West District of Ghana. Int J Infect Dis. 2025;1:107790.","journal-title":"Int J Infect Dis"},{"issue":"Suppl 5","key":"1333_CR29","doi-asserted-by":"publisher","first-page":"S503","DOI":"10.1093\/infdis\/jiz647","volume":"221","author":"JM Prada","year":"2020","unstructured":"Prada JM, Davis EL, Touloupou P, Stolk WA, Kontoroupis P, Smith ME, et al. Elimination or resurgence: modelling lymphatic filariasis after reaching the 1 % microfilaremia threshold. J Infect Dis. 2020;221(Suppl 5):S503\u20139.","journal-title":"J Infect Dis"},{"issue":"378","key":"1333_CR30","first-page":"20220280","volume":"2023","author":"NTGA Chandrasena","year":"1887","unstructured":"Chandrasena NTGA, Gunaratna IE, Ediriweera D, de Silva NR. Lymphatic filariasis and soil-transmitted helminthiases in Sri Lanka: the challenge of eliminating residual pockets of transmission. Philos Trans R Soc Lond B Biol Sci. 1887;2023(378):20220280.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"4","key":"1333_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231541","volume":"15","author":"FN Yokoly","year":"2020","unstructured":"Yokoly FN, Zahouli JBZ, M\u00e9it\u00e9 A, Opoku M, Kouassi BL, de Souza DK, et al. Low transmission of Wuchereria bancrofti in C\u00f4te d\u2019Ivoire: progress toward elimination. PLoS ONE. 2020;15(4): e0231541.","journal-title":"PLoS ONE"},{"issue":"11","key":"1333_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007861","volume":"13","author":"I Silumbwe","year":"2019","unstructured":"Silumbwe I, Hikabasa H, Zulu JM. How community engagement strategies shape participation in MDA programmes for lymphatic filariasis: Luangwa District, Zambia. PLoS Negl Trop Dis. 2019;13(11): e0007861.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"1333_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003167","volume":"4","author":"ZB Koricha","year":"2024","unstructured":"Koricha ZB, Abraha YG, Ababulgu SA, Abraham G, Morankar S. Community engagement in research addressing infectious diseases of poverty in sub-Saharan Africa: a qualitative systematic review. PLOS Glob Public Health. 2024;4(7): e0003167.","journal-title":"PLOS Glob Public Health"},{"issue":"1","key":"1333_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262693","volume":"17","author":"ET Lupenza","year":"2022","unstructured":"Lupenza ET, Gasarasi DB, Minzi OM. Lymphatic filariasis elimination status after seven rounds of MDA in Masasi District, Tanzania. PLoS ONE. 2022;17(1): e0262693.","journal-title":"PLoS ONE"},{"key":"1333_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13071-021-04644-2","volume":"14","author":"MA Dorkenoo","year":"2021","unstructured":"Dorkenoo MA, Tchankoni MK, Yehadji D, Yakpa K, Tchalim M, Sossou E, et al. Monitoring migrant groups as a post-validation surveillance approach to contain potential re-emergence of lymphatic filariasis in Togo. Parasit Vectors. 2021;14:134.","journal-title":"Parasit Vectors"},{"issue":"1","key":"1333_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4269\/ajtmh.22-0491","volume":"108","author":"ES Miri","year":"2023","unstructured":"Miri ES, Eigege A, Kahansim B, Nwodu K, Sambo Y, Mancha B, et al. Elimination of human onchocerciasis in Plateau and Nasarawa States. Nigeria Am J Trop Med Hyg. 2023;108(1):37\u201340.","journal-title":"Nigeria Am J Trop Med Hyg"},{"issue":"10","key":"1333_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006004","volume":"11","author":"DD Pam","year":"2017","unstructured":"Pam DD, de Souza DK, D\u2019Souza S, Opoku M, Sanda S, Nazaradden I, et al. Is MDA against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria. PLoS Negl Trop Dis. 2017;11(10): e0006004.","journal-title":"PLoS Negl Trop Dis"},{"key":"1333_CR38","first-page":"69","volume":"130","author":"ME Mwakitalu","year":"2014","unstructured":"Mwakitalu ME, Malecela MN, Pedersen EM, Mosha FW, Simonsen PE. Urban lymphatic filariasis in Tanga, Tanzania, after seven rounds of MDA. Acta Trop. 2014;130:69\u201374.","journal-title":"Acta Trop"},{"issue":"12","key":"1333_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008916","volume":"14","author":"CL Lau","year":"2020","unstructured":"Lau CL, Sheel M, Gass K, Fuimaono S, David MC, Won KY, et al. Potential strategies for strengthening surveillance of lymphatic filariasis in American Samoa after MDA. PLoS Negl Trop Dis. 2020;14(12): e0008916.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"1333_CR40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006583","volume":"10","author":"M Sheel","year":"2016","unstructured":"Sheel M, Sheridan S, Lau CL, Fuimaono S, Graves PM, Lammie PJ, Reddell S. Identifying residual transmission of lymphatic filariasis after mass drug administration: a comparison of school-based versus community-based surveillance in American Samoa. PLoS Negl Trop Dis. 2016;10(7): e0004776.","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"1333_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007115","volume":"13","author":"NK Biritwum","year":"2019","unstructured":"Biritwum NK, Frempong KK, Verver S, Odoom S, Alomatu B, Asiedu O, et al. Progress toward LF elimination in Ghana, 2000\u20132016: analysis of data from 430 communities. PLoS Negl Trop Dis. 2019;13(8): e0007115.","journal-title":"PLoS Negl Trop Dis"},{"key":"1333_CR42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijid.2022.02.006","volume":"117","author":"AM Cadavid Restrepo","year":"2022","unstructured":"Cadavid Restrepo AM, Gass K, Won KY, Sheel M, Robinson K, Graves PM, et al. Potential use of antibodies to provide an earlier indication of lymphatic filariasis resurgence in post-mass drug administration surveillance in American Samoa. Int J Infect Dis. 2022;117:378\u201386.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"1333_CR43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4269\/ajtmh.2008.79.480","volume":"79","author":"D Kyelem","year":"2008","unstructured":"Kyelem D, Biswas G, Bockarie MJ, Bradley MH, El-Setouhy M, Fischer PU, et al. Determinants of success in national lymphatic filariasis programmes. Am J Trop Med Hyg. 2008;79(4):480\u20134.","journal-title":"Am J Trop Med Hyg"},{"key":"1333_CR44","volume-title":"Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021\u20132030","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021\u20132030. Geneva: World Health Organization; 2020."},{"issue":"2","key":"1333_CR45","first-page":"108","volume":"11","author":"M Gonzales","year":"2019","unstructured":"Gonzales M, Baker MC, Celestino A, Morillo DS, Chambliss A, Adams S, et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo. Dominican Republic Int Health. 2019;11(2):108\u201318.","journal-title":"Dominican Republic Int Health"},{"key":"1333_CR46","unstructured":"World Health Organization. Guideline: Alternative mass drug administration regimens to eliminate lymphatic filariasis. WHO\/HTM\/NTD\/PCT\/2017.07. Geneva: World Health Organization; 2017."},{"key":"1333_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008314","volume":"14","author":"H Betts","year":"2020","unstructured":"Betts H, Martindale S, Chiphwanya J, Mkwanda S, Kabuluzi S, Mzilahowa T, Ngwira B, Matipula DE, Nankabirwa V, Chibwana A, Kelly-Hope LA. Significant improvement in quality of life following surgery for hydrocele caused by lymphatic filariasis in Malawi: a prospective cohort study. PLoS Negl Trop Dis. 2020;14: e0008314.","journal-title":"PLoS Negl Trop Dis"},{"key":"1333_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010805","volume":"17","author":"M Edmiston","year":"2023","unstructured":"Edmiston M, Atinbire S, Mensah EO, Mensah E, Alomatu B, Mensah KA, et al. Evaluating the availability and quality of services for lymphatic filariasis morbidity in Ghana. PLoS Negl Trop Dis. 2023;17: e0010805.","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"1333_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009968","volume":"15","author":"KY Won","year":"2021","unstructured":"Won KY, Gass K, Biamonte M, Dagne DA, Ducker C, Hanna C, et al. Diagnostics to support elimination of lymphatic filariasis: two target product profiles. PLoS Negl Trop Dis. 2021;15(11): e0009968.","journal-title":"PLoS Negl Trop Dis"},{"key":"1333_CR50","first-page":"43","volume":"10","author":"A Srividya","year":"2019","unstructured":"Srividya A, Subramanian S, Jambulingam P, Vijayakumar B, Dinesh RJ. Mapping and monitoring for a lymphatic filariasis elimination programme: a systematic review. Res Rep Trop Med. 2019;10:43\u201390.","journal-title":"Res Rep Trop Med"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-025-01333-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:24:11Z","timestamp":1757219051000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-025-01333-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1186\/s40249-025-01333-5","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Transmission Assessment Survey is an integral component of the Lymphatic Filariasis elimination programme and serves to evaluate the impact of Mass Drug Administration efforts. As such, formal ethical clearance was not required for this assessment. Nevertheless, ethical principles were strictly upheld throughout the study. Informed consent was obtained from both the participating schools and the parents or guardians of the children who took part in the assessment. The purpose of the survey was clearly explained, participation was voluntary, and the children had the right to opt out of the survey at any point.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors confirm that there are no financial, personal, or professional conflicts of interest that could have influenced the outcomes or interpretations of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}